Story perspectives

Biotech Stocks Surge Ahead of Major Regulatory Updates

1/26/2026

42 9

Summary

Story summary

On January 26, 2026, biotech stocks rose as investors awaited trial data and regulatory updates, with Sarepta Therapeutics up 9.65% ahead of a Phase 3 Duchenne muscular dystrophy webcast and Fractyl Health advancing.
Greenwich LifeSciences won FDA approval for GP2 vials, a key step toward commercialization.
Trevi Therapeutics published Phase 2b results, boosting investor confidence.
AEON Biopharma rose after confirming FDA meetings and securing shareholder approval for financing transactions.

1 of 1

Story summary

On January 26, 2026, biotech stocks rose as investors awaited trial data and regulatory updates, with Sarepta Therapeutics up 9.65% ahead of a Phase 3 Duchenne muscular dystrophy webcast and Fractyl Health advancing.
Greenwich LifeSciences won FDA approval for GP2 vials, a key step toward commercialization.
Trevi Therapeutics published Phase 2b results, boosting investor confidence.
AEON Biopharma rose after confirming FDA meetings and securing shareholder approval for financing transactions.